Interaction Between 17β-estradiol, Prolactin and Human Papillomavirus Induce E6/E7 Transcript and Modulate the Expression and Localization of Hormonal Receptors

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2019 Sep 12

PMID 31507337

Citations 12

Authors

Inocencia Guadalupe Ramirez-Lopez

Adrian Ramirez de Arellano

Luis Felipe Jave-Suarez

Christian David Hernandez-Silva

Mariel Garcia-Chagollan

Jorge Hernandez-Bello

Edgar I Lopez-Pulido

Jose Macias-Barragan

Margarita Montoya-Buelna

Jose Francisco Munoz-Valle

Ana Laura Pereira-Suarez

Affiliations

Soon will be listed here.

Abstract

Background: Cervical cancer (CC) is the second most common cancer in less developed countries and the second leading cause of death by cancer in women worldwide. The 99% of CC patients are infected with the Human Papilloma Virus (HPV), being HPV16 and HPV18 infection the most frequent. Even though HPV is considered to be a necessary factor for the development of CC, it is not enough, as it requires the participation of other factors such as the hormonal ones. Several studies have demonstrated the requirement of estrogen and its receptors (ERα, ERβ, and GPER) in the precursor lesions progress towards CC. Also, prolactin (PRL) and its receptor (PRLR) have been associated with CC. The molecular mechanisms underlying the cooperation of these hormones with the viral oncoproteins are not well elucidated. For this reason, this study focused on analyzing the contribution of 17β-estradiol (E2), PRL, and HPV on the expression and localization of hormone receptors, as well as to evaluate whether these hormones may promote greater expression of HPV oncogenes and contribute to tumor progression.

Methods: qPCR was used to evaluate the effect of E2 and PRL on the expression of E6 and E7 oncoproteins in HeLa and SiHa cervical cancer cells lines. HaCaT cells were transduced with the viral oncogenes E6 and E7 from HPV 16 and 18. ERα, ERβ, GPER, and PRLR expression and localization were evaluated by qPCR, Western blot and immunofluorescence.

Results: E2 and PRL induce E6/E7 oncogenes expression in HeLa and SiHa cells. E6 and E7 oncogenes of HPV16/18 significantly increased the protein expression of ERα, GPER, and PRLR. ERβ was positively regulated only by E6 oncogenes of HPV16/18. Besides, some of these oncogenes modify the location of PRLR toward cytoplasm, and ERα, ERβ, and GPER mainly to the nucleus.

Conclusion: Our studies suggest that the mutual regulation between E2, PRL, and HPV oncogenes could cooperate with the carcinogenesis process in CC.

Citing Articles

The G-Protein-Coupled Estrogen Receptor Agonist G-1 Mediates Antitumor Effects by Activating Apoptosis Pathways and Regulating Migration and Invasion in Cervical Cancer Cells.

Gaxiola-Rubio A, Jave-Suarez L, Hernandez-Silva C, Ramirez-de-Arellano A, Villegas-Pineda J, Lizarraga-Ledesma M Cancers (Basel). 2024; 16(19).

PMID: 39409923 PMC: 11475807. DOI: 10.3390/cancers16193292.

Challenging the Norm: The Unrecognized Impact of Soluble Guanylyl Cyclase Subunits in Cancer.

Pino M, Rocca M, Acosta L, Cabilla J Int J Mol Sci. 2024; 25(18).

PMID: 39337539 PMC: 11432225. DOI: 10.3390/ijms251810053.

HPV and Cervical Cancer: Molecular and Immunological Aspects, Epidemiology and Effect of Vaccination in Latin American Women.

Hernandez-Silva C, Ramirez de Arellano A, Pereira-Suarez A, Ramirez-Lopez I Viruses. 2024; 16(3).

PMID: 38543693 PMC: 10974876. DOI: 10.3390/v16030327.

Activation of G-Protein-Coupled Estrogen Receptor 1 (GPER1) Reduces Progression of Vulvar Carcinoma Cells.

Loris J, Hanesch L, Bauerschmitz G, Gallwas J, Grundker C Int J Mol Sci. 2023; 24(18).

PMID: 37762008 PMC: 10530864. DOI: 10.3390/ijms241813705.

The Role of G Protein-Coupled Estrogen Receptor (GPER) in Vascular Pathology and Physiology.

Xu F, Ma J, Wang X, Wang X, Fang W, Sun J Biomolecules. 2023; 13(9).

PMID: 37759810 PMC: 10526873. DOI: 10.3390/biom13091410.

References

Frasor J, Park K, Byers M, Telleria C, Kitamura T, Djiane J . Differential roles for signal transducers and activators of transcription 5a and 5b in PRL stimulation of ERalpha and ERbeta transcription. Mol Endocrinol. 2001; 15(12):2172-81. DOI: 10.1210/mend.15.12.0745. View

Lee D, Kim H, Jeong K, Shim Y, Horikawa I, Barrett J . Human papillomavirus E2 down-regulates the human telomerase reverse transcriptase promoter. J Biol Chem. 2002; 277(31):27748-56. DOI: 10.1074/jbc.M203706200. View

Lee D, Kim B, Kim I, Cho E, Satterwhite D, Kim S . The human papilloma virus E7 oncoprotein inhibits transforming growth factor-beta signaling by blocking binding of the Smad complex to its target sequence. J Biol Chem. 2002; 277(41):38557-64. DOI: 10.1074/jbc.M206786200. View

Brake T, Lambert P . Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A. 2005; 102(7):2490-5. PMC: 548999. DOI: 10.1073/pnas.0409883102. View

Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun J, Ali S . Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res. 2006; 66(3):1824-32. DOI: 10.1158/0008-5472.CAN-05-2292. View

Duan R, Ginsburg E, Vonderhaar B . Estrogen stimulates transcription from the human prolactin distal promoter through AP1 and estrogen responsive elements in T47D human breast cancer cells. Mol Cell Endocrinol. 2007; 281(1-2):9-18. DOI: 10.1016/j.mce.2007.10.004. View

Diaz-Chavez J, Hernandez-Pando R, Lambert P, Gariglio P . Down-regulation of transforming growth factor-beta type II receptor (TGF-betaRII) protein and mRNA expression in cervical cancer. Mol Cancer. 2008; 7:3. PMC: 2248208. DOI: 10.1186/1476-4598-7-3. View

Chung S, Wiedmeyer K, Shai A, Korach K, Lambert P . Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res. 2008; 68(23):9928-34. PMC: 2596671. DOI: 10.1158/0008-5472.CAN-08-2051. View

Gonzalez L, Zambrano A, Lazaro-Trueba I, Lopez E, Gonzalez J, Martin-Perez J . Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene. 2009; 28(10):1298-308. DOI: 10.1038/onc.2008.473. View

10.

Chen Y, Huang K, Chen K, Walker A . Prolactin and estradiol utilize distinct mechanisms to increase serine-118 phosphorylation and decrease levels of estrogen receptor alpha in T47D breast cancer cells. Breast Cancer Res Treat. 2009; 120(2):369-77. DOI: 10.1007/s10549-009-0400-7. View

11.

Rampias T, Boutati E, Pectasides E, Sasaki C, Kountourakis P, Weinberger P . Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res. 2010; 8(3):433-43. DOI: 10.1158/1541-7786.MCR-09-0345. View

12.

Arendt L, Rugowski D, Grafwallner-Huseth T, Garcia-Barchino M, Rui H, Schuler L . Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res. 2011; 13(1):R11. PMC: 3109579. DOI: 10.1186/bcr2819. View

13.

Prossnitz E, Barton M . The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol. 2011; 7(12):715-26. PMC: 3474542. DOI: 10.1038/nrendo.2011.122. View

14.

Halim T, Farooqi A, Zaman F . Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes. Cancer Cell Int. 2013; 13(1):61. PMC: 3691735. DOI: 10.1186/1475-2867-13-61. View

15.

OLeary K, Jallow F, Rugowski D, Sullivan R, Sinkevicius K, Greene G . Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo. Endocrinology. 2013; 154(12):4483-92. PMC: 3836081. DOI: 10.1210/en.2013-1533. View

16.

Nitze L, Galsgaard E, Din N, Lund V, Rasmussen B, Werner Berchtold M . Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer. Breast Cancer Res Treat. 2013; 142(1):31-44. PMC: 3825490. DOI: 10.1007/s10549-013-2731-7. View

17.

Lopez-Pulido E, Munoz-Valle J, Del Toro-Arreola S, Jave-Suarez L, Bueno-Topete M, Estrada-Chavez C . High expression of prolactin receptor is associated with cell survival in cervical cancer cells. Cancer Cell Int. 2013; 13(1):103. PMC: 4016267. DOI: 10.1186/1475-2867-13-103. View

18.

Ascencio-Cedillo R, Lopez-Pulido E, Munoz-Valle J, Villegas-Sepulveda N, Del Toro-Arreola S, Estrada-Chavez C . Prolactin and prolactin receptor expression in cervical intraepithelial neoplasia and cancer. Pathol Oncol Res. 2014; 21(2):241-6. DOI: 10.1007/s12253-014-9814-6. View

19.

Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R . Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol. 1989; 70 ( Pt 8):2227-32. DOI: 10.1099/0022-1317-70-8-2227. View

20.

Barcus C, Holt E, Keely P, Eliceiri K, Schuler L . Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells. PLoS One. 2015; 10(1):e0116891. PMC: 4301649. DOI: 10.1371/journal.pone.0116891. View